Biosimilars in Oncology: Latest Trends and Regulatory Status
Authors:
- Deeksha JoshiDJDeeksha Joshi
- Rubiya KhursheedRKRubiya Khursheed
- Saurabh GuptaSGSaurabh Gupta
- Diksha WadhwaDWDiksha Wadhwa
- Thakur Gurjeet SinghTSThakur Gurjeet Singh
- Sumit SharmaSSSumit Sharma
- Sejal PorwalSPSejal Porwal
- Swati GauniyalSGSwati Gauniyal
- Sukriti VishwasSVSukriti Vishwas
- Sanjay GoyalSGSanjay Goyal
- Gaurav GuptaGGGaurav Gupta
- Rajaraman D. EriRERajaraman D. Eri
Open Access
- 5 December 2022
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2721
Abstract
Biologic-based medicines are used to treat a variety of diseases and account for around one-quarter of the worldwide pharmaceutical market. The use of biologic medications among cancer patients has resulted in substantial advancements in cancer treatment and supportive care. Biosimilar medications (or biosimilars) are very similar to the reference biologic drugs, although they are not identical. As patent protection for some of the most extensively used biologics begins to expire, biosimilars have the potential to enhance access and provide lower-cost options for cancer treatment. Initially, regulatory guidelines were set up in Europe in 2003, and the first biosimilar was approved in 2006 in Europe. Many countries, including the United States of America (USA), Canada, and Japan, have adopted Europe’s worldwide regulatory framework. The use of numerous biosimilars in the treatment and supportive care of cancer has been approved and, indeed, the count is set to climb in the future around the world. However, there are many challenges associated with biosimilars, such as cost, immunogenicity, lack of awareness, extrapolation of indications, and interchangeability. The purpose of this review is to provide an insight into biosimilars, which include various options available for oncology, and the associated adverse events. We compare the regulatory guidelines for biosimilars across the world, and also present the latest trends and challenges in medical oncology both now and in the future, which will assist healthcare professionals, payers, and patients in making informed decisions, increasing the acceptance of biosimilars in clinical practice, increasing accessibility, and speeding up the health and economic benefits associated with biosimilars.Keywords
This publication has 72 references indexed in Scilit:
- Bevacizumab treatment for advanced non-small cell lung cancer: A case reportOncology Letters, 2013
- Clinical research regulation in India-history, development, initiatives, challenges and controversies: Still long way to goJournal of Pharmacy and Bioallied Sciences, 2013
- Potential Regulatory and Commercial Environment for Biosimilars in Latin AmericaValue in Health Regional Issues, 2012
- Thirty years of preclinical safety evaluation of biopharmaceuticals: did scientific progress lead to appropriate regulatory guidance?Expert Opinion on Drug Safety, 2012
- Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United StatesClinical Therapeutics, 2012
- Quality, safety and efficacy of follow-on biologics in JapanBiologicals, 2011
- Biosimilar agents in oncology/haematology: from approval to practiceEuropean Journal of Haematology, 2010
- Biosimilars: pharmacovigilance and risk managementPharmacoepidemiology and Drug Safety, 2010
- Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysisCanadian Medical Association Journal, 2009
- Pure Red-Cell Aplasia and Epoetin TherapyNew England Journal of Medicine, 2004